心通醫療-B：VITAFLOW LIBERTY® FLEX獲國家藥監局批准註冊

新浪港股

2024-12-18

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　心通醫療-B（02160）發佈公告，於2024年12月16日，集團自主研發的第三代經導管主動脈瓣植入術（TAVI）產品VitaFlow Liberty® Flex經導管主動脈瓣可回收可控彎輸送系統（‘VitaFlow Liberty® Flex’）獲得中國國家藥品監督管理局頒發的註冊批准。

　　VitaFlow Liberty® Flex爲VitaFlow Liberty®輸送系統的升級款產品，可與集團已獲批的主動脈瓣膜配合使用，其傳承了VitaFlow Liberty®輸送系統的所有優勢，並創新性地增加了3D空間調彎功能。其獨有的內管調彎技術可使瓣膜在釋放過程中保持同軸，植入更穩定精準，過弓以及跨瓣也更順暢安全。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492908910"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492908910\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492908910?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-12-18 08:02","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2492908910","market":"hk","top_or_hot":-1,"title":"心通醫療-B：VITAFLOW LIBERTY® FLEX獲國家藥監局批准註冊","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02160.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/02160\">心通醫療-B</a></span><span></span>（02160）發佈公告，於2024年12月16日，集團自主研發的第三代經導管主動脈瓣植入術（TAVI）產品VitaFlow Liberty® Flex經導管主動脈瓣可回收可控彎輸送系統（‘VitaFlow Liberty® Flex’）獲得中國國家藥品監督管理局頒發的註冊批准。</p>\n<p>　　VitaFlow Liberty® Flex爲VitaFlow Liberty®輸送系統的升級款產品，可與集團已獲批的主動脈瓣膜配合使用，其傳承了VitaFlow Liberty®輸送系統的所有優勢，並創新性地增加了3D空間調彎功能。其獨有的內管調彎技術可使瓣膜在釋放過程中保持同軸，植入更穩定精準，過弓以及跨瓣也更順暢安全。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心通醫療-B：VITAFLOW LIBERTY® FLEX獲國家藥監局批准註冊</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心通醫療-B：VITAFLOW LIBERTY® FLEX獲國家藥監局批准註冊\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2024-12-18 08:02</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02160.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/02160\">心通醫療-B</a></span><span></span>（02160）發佈公告，於2024年12月16日，集團自主研發的第三代經導管主動脈瓣植入術（TAVI）產品VitaFlow Liberty® Flex經導管主動脈瓣可回收可控彎輸送系統（‘VitaFlow Liberty® Flex’）獲得中國國家藥品監督管理局頒發的註冊批准。</p>\n<p>　　VitaFlow Liberty® Flex爲VitaFlow Liberty®輸送系統的升級款產品，可與集團已獲批的主動脈瓣膜配合使用，其傳承了VitaFlow Liberty®輸送系統的所有優勢，並創新性地增加了3D空間調彎功能。其獨有的內管調彎技術可使瓣膜在釋放過程中保持同軸，植入更穩定精準，過弓以及跨瓣也更順暢安全。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-18/doc-inczvssx8327360.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0689626769.HKD","symbol_name":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-18/doc-inczvssx8327360.shtml","article_id":"2492908910","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492908910","pubTimestamp":1734480120,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　心通醫療-B發佈公告，於2024年12月16日，集團自主研發的第三代經導管主動脈瓣植入術產品VitaFlow Liberty Flex經導管主動脈瓣可回收可控彎輸送系統獲得中國國家藥品監督管理局頒發的註冊批准。　　VitaFlow Liberty Flex為VitaFlow Liberty輸送系統的升級款產品，可與集團已獲批的主動脈瓣膜配合使用，其傳承了VitaFlow Liberty輸送系統的所有優勢，並創新性地增加了3D空間調彎功能。其獨有的內管調彎技術可使瓣膜在釋放過程中保持同軸，植入更穩定精準，過弓以及跨瓣也更順暢安全。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","BK4145":"电子制造服务","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","BK1100":"医疗保健设备","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","BK1583":"高瓴概念","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","FLEX":"伟创力国际","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4588":"碎股","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","BK4512":"苹果概念","02160":"心通医疗-B","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD"},"translate_title":"Xintong Medical-B: VITAFLOW LIBERTY ® FLEX was approved and registered by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1,"FLEX":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　心通醫療-B（02160）發佈公告，於2024年12月16日，集團自主研發的第三代經導管主動脈瓣植入術（TAVI）產品VitaFlow Liberty® Flex經導管主動脈瓣可回收可控彎輸送系統（‘VitaFlow Liberty® Flex’）獲得中國國家藥品監督管理局頒發的註冊批准。\n　　VitaFlow Liberty® Flex為VitaFlow Liberty®輸送系統的升級款產品，可與集團已獲批的主動脈瓣膜配合使用，其傳承了VitaFlow Liberty®輸送系統的所有優勢，並創新性地增加了3D空間調彎功能。其獨有的內管調彎技術可使瓣膜在釋放過程中保持同軸，植入更穩定精準，過弓以及跨瓣也更順暢安全。\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}